Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study
Rachel Cusatis(Medical College of Wisconsin), Surbhi Sidana(Palo Alto University), Irena Tan(Stanford Medicine), Emma Crawford(Stanford University), Matthew J. Frank(Stanford Blood Center), Anita D’Souza, Idayat Akinola(Medical College of Wisconsin), Kathryn E. Flynn(Medical College of Wisconsin), Claire Piehowski(Medical College of Wisconsin), Jennifer M. Knight(Medical College of Wisconsin), Juliana Craig(Stanford Medicine), David B. Miklos(Stanford University), Lori Muffly(Stanford University), Nirav N. Shah(Medical College of Wisconsin), Aline Thiengmany(Stanford University)
Cited by 19
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1
|Cell|1999|559